Attorney General T.J. Donovan
Attention: Ryan Kriger, Assistant Attorney General

AstraZeneca

VT S.92 (Act 193, Sec.10.18 V.S.A § 4637) Reporting

Overview

In Accordance with the requirements of subsection B set forth in the VT S.92 (Act 193, Sec.10.18 V.S.A § 4637) regulation, this is AstraZeneca's 30-day post launch notice of the introduction of FASENRA Pen™ (benralizumab), into the state of Vermont.

The Product

FASENRA® (Benralizumab) is indicated as an add-on maintenance treatment of patients 12 years and older with severe eosinophilic asthma. FASENRA® (Benralizumab) is not indicated for treatment of other eosinophilic conditions or for the relief of acute bronchospasm or status asthmaticus.

Marketing Plans

AstraZeneca will engage 2 sales representative(s) to cover the state of Vermont. Patient brochures, clinical data, dosing/administration guides, and samples may be left behind in offices for informational purposes. In addition to sales representative promotion, Fasenra® commercials are televised on the national broadcast networks.

AstraZeneca provides online resources via FasenraHCP.com for US healthcare professionals and Fasenra.com for patients and consumers. Patients may register for the FASENRA 360 support program via the website which will enroll them in a digital relationship marketing program to receive materials such as disease state education, patient brochures, and dosing reminders. The FASENRA® patient savings program for eligible commercially insured patients will be available for patients in Vermont and can be found on Fasenra.com.

FASENRA® is currently marketed in 47 countries.

Pricing Plans

The price for FASENRA Pen™ (benralizumab) in Vermont will be the same across the United States.

Branded Name	Generic Name	NDC	WAC Package Price	Effective Date
Fasenra Pen	benralizumab	00310-1830-30	$4,895.74	10/03/19

When setting the price of medicines AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value.

Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.

Estimated Volume of Patients

The estimated volume of patients that could benefit from FASENRA Pen™ (benralizumab) per the indication of treatment for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype is approximately 1 million patients in the entire US.

Breakthrough Designation

FASENRA Pen™ (benralizumab) did not have approval under FDA Priority Review nor receive FDA Breakthrough Designation. FASENRA Pen™ (benralizumab) received FDA approval on October 3, 2019.

Date of Acquisition

FASENRA Pen™ (benralizumab) was developed by AstraZeneca with MedImmune, AstraZeneca's global biologics research and development arm, and is in-licensed from BioWa, Inc., a wholly-owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan.